Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor positive, HER2 negative metastatic breast cancer
{{output}}
Introduction: Estrogen receptor positive, HER2 negative (ER+/HER2-) metastatic breast cancer represents a major therapeutic challenge due to the frequent development of endocrine resistance. This review focuses on ESR1 mutations ... ...
